Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting

被引:12
|
作者
Eugenia Socias, M. [1 ,2 ]
Dong, Huiru [1 ]
Wood, Evan [1 ,2 ]
Nolan, Seonaid [1 ,2 ]
Hayashi, Kanna [1 ,3 ]
Kerr, Thomas [1 ,2 ]
Milloy, M-J [1 ,2 ]
机构
[1] British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada
[2] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[3] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada
基金
加拿大健康研究院;
关键词
NONFATAL HEROIN OVERDOSE; ANTIRETROVIRAL THERAPY; BARRIERS; DEPENDENCE; PEOPLE;
D O I
10.1016/j.amepre.2020.07.006
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: Retention in opioid agonist therapy consistently has been linked with improved outcomes among people with opioid use disorder. However, less is known about the links between patterns of engagement in opioid agonist therapy over the long term and overdose risk. This study assesses the association of opioid agonist therapy retention trajectories with nonfatal overdose. Methods: Data were drawn from 2 community-recruited prospective cohorts of people who use drugs in Vancouver, Canada. Latent class growth analysis was used to identify trajectories of opioid agonist therapy retention among people with opioid use disorder initiating therapy, and generalized estimating equations assessed the association of these trajectories with nonfatal overdose events after opioid agonist therapy initiation. Results: Between 2005 and 2018, among 438 opioid agonist therapy initiators, 4 retention trajectories were identified: consistently high (35.6%), increasing (26.0%), consistently low (23.3%), and decreasing (15.1%) opioid agonist therapy engagement. During the study period, there were 371 nonfatal overdose events, with 179 (40.1%) participants reporting >= 1. In adjusted analysis, the consistently low (AOR=1.73, 95% CI=1.10, 2.71) and decreasing (AOR=1.87, 95% CI=1.18, 2.95) retention trajectories were positively associated with increased odds of nonfatal overdose compared with the consistently high opioid agonist therapy retention class. Conclusions: Suboptimal trajectories of opioid agonist therapy retention were associated with an increased likelihood of nonfatal overdose. These findings suggest that reducing the barriers to sustained engagement in opioid agonist therapy will be critical to address North America's overdose epidemic. (C) 2020 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 5 条
  • [1] Trajectories of retention in opioid agonist therapy in a Canadian setting
    Socias, M. Eugenia
    Dong, Huiru
    Wood, Evan
    Brar, Rupinder
    Richardson, Lindsey
    Hayashi, Kanna
    Kerr, Thomas
    Milloy, M-J
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 77
  • [2] Density of low-barrier opioid agonist clinics and risk of non-fatal overdose during a community-wide overdose crisis: A spatial analysis
    Amram, Ofer
    Socias, Eugenia
    Nosova, Ekaterina
    Kerr, Thomas
    Wood, Evan
    DeBeck, Kora
    Hayashi, Kanna
    Fairbairn, Nadia
    Montaner, Julio
    Milloy, M. J.
    SPATIAL AND SPATIO-TEMPORAL EPIDEMIOLOGY, 2019, 30
  • [3] Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services
    Krawczyk, Noa
    Mojtabai, Ramin
    Stuart, Elizabeth A.
    Fingerhood, Michael
    Agus, Deborah
    Lyons, B. Casey
    Weiner, Jonathan P.
    Saloner, Brendan
    ADDICTION, 2020, 115 (09) : 1683 - 1694
  • [4] Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study
    Pearce, Lindsay A.
    Min, Jeong Eun
    Piske, Micah
    Zhou, Haoxuan
    Homayra, Fahmida
    Slaunwhite, Amanda
    Irvine, Mike
    McGowan, Gina
    Nosyk, Bohdan
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 368
  • [5] Non-fatal overdose risk during and after opioid agonist treatment: A primary care cohort study with linked hospitalisation and mortality records br
    Domzaridou, Eleni
    Carr, Matthew J.
    Webb, Roger T.
    Millar, Tim
    Ashcroft, Darren M.
    LANCET REGIONAL HEALTH-EUROPE, 2022, 22